Neurocrine’s Crinecerfont Draws Cautious Optimism On Clinical Meaningfulness
The biotech plans to file for approval for congenital adrenal hyperplasia (CAH) next year and is now looking ahead to a pediatric study, which may pose lower risk.
You may also be interested in...
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.
The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.
Deal Snapshot: The companies had announced the deal back in February 2021, but citing its “strategic focus,” AbbVie told Caribou it was backing out.